The Role and Future of Functional Graphenic Materials in Biomedical and Human Health Applications
Arnold AM., Singh J., Sydlik SA.
Narrative Review, published in Biomacromolecules (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Biomacromolecules (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40101190
- PMCID
- PMC12004540
- DOI
- 10.1021/acs.biomac.4c01431
- Citations
- 1
Abstract (original English)
Functional graphenic materials (FGMs) are materials derived from graphene oxide (GO) that hold a plethora of applications from electronics to nanomedicine. In this Perspective, we examine the history and evolution of biomedical applications of this carbon-based macromolecule. Following the carbon nanotube (CNT) movement, GO and FGMs became nanocarbons of interest because of their low cost and versatile functionality. The tunable chemistry enabled our work on FGMs coupled with biomacromolecules and allows FGMs to plays an important role in many biomedical applications, from tissue regeneration to controlled delivery. As we work to develop this material, it is critical to consider toxicity implications─in fresh materials as well as in degradation products. With this understanding, FGMs also hold potential roles in human health and environmental sustainability, making FGMs an important contemporary biomacromolecule.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.